Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07679893 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis
A Phase 2 study, sponsored by Mannkind Corporation.
- Not yet
- Registry status
- Phase 2
- Development phase
- 210
- Enrollment target
NCT07679893 is a Phase 2 study that has not yet begun recruiting, run by Mannkind Corporation. The registered enrollment target is 210 participants.
The verdict
NCT07679893, a Phase 2 study, has not yet begun recruiting, sponsored by Mannkind Corporation.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 210 participants
- Enrollment target
Study Summary
This trial is a randomized, double-blind, placebo-controlled study evaluating the safety and preliminary efficacy of inhaled Nintedanib Dry Powder Inhalation (DPI) in adults with idiopathic pulmonary fibrosis (IPF). Participants are randomized to receive either 2 mg QID, 4 mg BID, or matching placebo for 12 weeks, followed by a 24-week open-label extension in which all participants receive active treatment. The primary focus is on safety-particularly bronchospasm events, lung function changes (FEV1, FEV1/FVC), and adverse event rates and assessing the effectiveness of nintedanib DPI in treating IPF.
Interventions
- DRUG Placebo
- DRUG Nintedanib Dry Powder Inhalation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2026-06-30 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07679893
The ClinicalTrials.gov registry entry for NCT07679893 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07679893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07679893 about?
NCT07679893 is a clinical study titled "Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis". This trial is a randomized, double-blind, placebo-controlled study evaluating the safety and preliminary efficacy of inhaled Nintedanib Dry Powder Inhalation (DPI) in adults with idiopathic pulmonary fibrosis (IPF). Participants are randomized to receive either 2 mg QID, 4 mg BID, or matching placeb...
What is the current status of trial NCT07679893?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2026-06-30. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07679893?
The interventions under investigation include: Placebo (DRUG), Nintedanib Dry Powder Inhalation (DRUG).
Who is sponsoring clinical trial NCT07679893?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.